Jan Musiałkiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Musiałkiewicz has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Paweł Komarnicki
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland
3 shared publications Adam Maciejewski
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
2 shared publications- Adam Maciejewski
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland
2 shared publications Marek Ruchała
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
2 shared publications- Marek Ruchała
Department of Endocrinology, Metabolism and Internal Medicine, Poznań University of Medical Sciences 1
2 shared publications Paweł Gut
Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4874
Prognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors
Neuroendocrine tumors (NETs) constitute a heterogeneous and predominantly malignant group of neuroendocrine neoplasms that arise from endocrine cells dispersed throughout the body. Their clinical presentation, biological behavior, prognosis, and therapeutic management vary considerably depending on the primary tumor location and hormonal activity. Despite substantial progress in understanding the biology of NETs, identifying reliable molecular biomarkers for diagnosis, prognosis, and prediction of treatment response remains a major challenge. Increasing attention has therefore been devoted to the molecular characterization of NETs, with particular focus on recurrent genetic alterations that may contribute to tumor initiation and progression. In this review, we summarize current knowledge and recent findings referring to certain genes involved in the tumorigenesis of pancreatic and intestinal neuroendocrine tumors. We chose the genes based on data from the COSMIC (Catalogue of Somatic Mutations in Cancer) database, which compiles somatic mutations identified across numerous human cancers. We outline the biological functions of these changes and discuss their potential prognostic and predictive role as molecular markers. We also discuss their clinical relevance in both sporadic and familial forms of NETs, alongside their implications for future research and personalized management strategies.
- 28 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4874
Open AccessPrognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors
Neuroendocrine tumors (NETs) constitute a heterogeneous and predominantly malignant group of neuroendocrine neoplasms that arise from endocrine cells dispersed throughout the body. Their clinical presentation, biological behavior, prognosis, and therapeutic management vary considerably depending on the primary tumor location and hormonal activity. Despite substantial progress in understanding the biology of NETs, identifying reliable molecular biomarkers for diagnosis, prognosis, and prediction of treatment response remains a major challenge. Increasing attention has therefore been devoted to the molecular characterization of NETs, with particular focus on recurrent genetic alterations that may contribute to tumor initiation and progression. In this review, we summarize current knowledge and recent findings referring to certain genes involved in the tumorigenesis of pancreatic and intestinal neuroendocrine tumors. We chose the genes based on data from the COSMIC (Catalogue of Somatic Mutations in Cancer) database, which compiles somatic mutations identified across numerous human cancers. We outline the biological functions of these changes and discuss their potential prognostic and predictive role as molecular markers. We also discuss their clinical relevance in both sporadic and familial forms of NETs, alongside their implications for future research and personalized management strategies.
- 8 October 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (3) , 299-302
Multiple endocrinopathies presenting simultaneously with insulinoma as the leading manifestation
- 8 October 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (3) , 299-302
Multiple endocrinopathies presenting simultaneously with insulinoma as the leading manifestation
- Open Access
- 29 August 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (9)
Longitudinal analysis of serum alpha-fetoprotein in stable and progressive metastatic pancreatic neuroendocrine tumours
Graphical Background: Neuroendocrine tumours (NETs) are a heterogeneous group of rare neoplasms arising from neuroendocrine cells, most commonly found in the gastrointestinal tract and pancreas. Despite novel diagnostic techniques, identifying reliable biomarkers for NETs still remains a challenge. Objectives: Our study explores the diagnostic, monitoring and prognostic value of alpha-fetoprotein (AFP) in pancreatic NETs. Materials and methods: We recruited 41 adult patients diagnosed with liver-metastatic non-functioning pancreatic NETs. Serum AFP levels were assessed at 3-month intervals over a span of 4 years. For comparative purposes, we analysed data in relation to sex, age, liver tumour burden (LTB; <10%, 10–25%), tumour grade based on the WHO 2022 classification (G1, G2), and treatment response at baseline as defined by RECIST 1.1 criteria (SD – stable disease, PD – progressive disease). Every patient underwent treatment with somatostatin analogues during the study period. Results: Elevated AFP concentrations showed a continuous upward trend across all participants and were significantly associated with indicators of more aggressive disease: greater LTB (10–25%, P < 0.001), higher tumour grade (G2, P < 0.001), and progression of disease (PD, P < 0.001). No statistically significant differences in AFP levels were observed in relation to age or sex. Conclusion: AFP consistently increases in patients with progressive pancreatic NETs compared to patients with SD at baseline. The potential utility of AFP measurements requires further follow-up studies, especially as a prognostic biomarker.
- 29 August 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (9)
Open AccessLongitudinal analysis of serum alpha-fetoprotein in stable and progressive metastatic pancreatic neuroendocrine tumours
Graphical Background: Neuroendocrine tumours (NETs) are a heterogeneous group of rare neoplasms arising from neuroendocrine cells, most commonly found in the gastrointestinal tract and pancreas. Despite novel diagnostic techniques, identifying reliable biomarkers for NETs still remains a challenge. Objectives: Our study explores the diagnostic, monitoring and prognostic value of alpha-fetoprotein (AFP) in pancreatic NETs. Materials and methods: We recruited 41 adult patients diagnosed with liver-metastatic non-functioning pancreatic NETs. Serum AFP levels were assessed at 3-month intervals over a span of 4 years. For comparative purposes, we analysed data in relation to sex, age, liver tumour burden (LTB; <10%, 10–25%), tumour grade based on the WHO 2022 classification (G1, G2), and treatment response at baseline as defined by RECIST 1.1 criteria (SD – stable disease, PD – progressive disease). Every patient underwent treatment with somatostatin analogues during the study period. Results: Elevated AFP concentrations showed a continuous upward trend across all participants and were significantly associated with indicators of more aggressive disease: greater LTB (10–25%, P < 0.001), higher tumour grade (G2, P < 0.001), and progression of disease (PD, P < 0.001). No statistically significant differences in AFP levels were observed in relation to age or sex. Conclusion: AFP consistently increases in patients with progressive pancreatic NETs compared to patients with SD at baseline. The potential utility of AFP measurements requires further follow-up studies, especially as a prognostic biomarker.
- Open Access
Serum Visfatin/eNAMPT as a Biomarker in Pancreatic and Small Intestine Neuroendocrine Tumors: A Cross-Sectional Study and Future Perspectives
Background : Neuroendocrine tumors (NETs) remain a problematic area in endocrine oncology due to their non-specific symptoms and lack of reliable biomarkers. Visfatin/eNAMPT’s involvement in tumorigenesis has been described in several malignancies. In NETs, NAMPT inhibition was explored as a potential therapeutic option; however, serum visfatin and its role as a biomarker have not been studied. Objectives: We aimed to measure serum visfatin concentrations in NETs and evaluate visfatin’s potential as a diagnostic biomarker. Methods: We conducted a single-center, cross-sectional study of 77 patients with NETs (33 pancreatic and 44 small intestinal) and 29 controls. Patient demographics, tumor characteristics, and clinical data were analyzed, and serum visfatin levels were measured using ELISA. Statistical analyses were performed in Python, including Mann–Whitney U and Kruskal–Wallis tests, Spearman’s correlation, multiple linear regression, and ROC curve analysis. Results: Serum visfatin was higher in NETs compared to controls (median [IQR]: 6.94 [2.11–236.17] vs. 1.59 [1.1–9.24] ng/mL, p = 0.004). ROC curves showed moderate diagnostic performance (AUC = 0.68), with concentrations above 2.11 ng/mL achieving 75.3% sensitivity and 58.6% specificity. In NETs, visfatin did not differ based on WHO grade (G1/G2, p = 0.31), primary site (pancreas/small intestine, p = 0.95), sex (p = 0.89), age (p = 0.13), and when stratified by primary site and grade (p = 0.18). Multiple linear regression confirmed no association between visfatin and the study variables (R-squared = 0.036, all p > 0.2). Conclusions: This is the first study examining serum visfatin as a diagnostic biomarker in NETs. Visfatin concentrations show moderate discriminatory ability between NETs and controls, independent of tumor and clinical characteristics. Further research should involve larger cohorts and comparisons to established biomarkers.
Open AccessSerum Visfatin/eNAMPT as a Biomarker in Pancreatic and Small Intestine Neuroendocrine Tumors: A Cross-Sectional Study and Future Perspectives
Background : Neuroendocrine tumors (NETs) remain a problematic area in endocrine oncology due to their non-specific symptoms and lack of reliable biomarkers. Visfatin/eNAMPT’s involvement in tumorigenesis has been described in several malignancies. In NETs, NAMPT inhibition was explored as a potential therapeutic option; however, serum visfatin and its role as a biomarker have not been studied. Objectives: We aimed to measure serum visfatin concentrations in NETs and evaluate visfatin’s potential as a diagnostic biomarker. Methods: We conducted a single-center, cross-sectional study of 77 patients with NETs (33 pancreatic and 44 small intestinal) and 29 controls. Patient demographics, tumor characteristics, and clinical data were analyzed, and serum visfatin levels were measured using ELISA. Statistical analyses were performed in Python, including Mann–Whitney U and Kruskal–Wallis tests, Spearman’s correlation, multiple linear regression, and ROC curve analysis. Results: Serum visfatin was higher in NETs compared to controls (median [IQR]: 6.94 [2.11–236.17] vs. 1.59 [1.1–9.24] ng/mL, p = 0.004). ROC curves showed moderate diagnostic performance (AUC = 0.68), with concentrations above 2.11 ng/mL achieving 75.3% sensitivity and 58.6% specificity. In NETs, visfatin did not differ based on WHO grade (G1/G2, p = 0.31), primary site (pancreas/small intestine, p = 0.95), sex (p = 0.89), age (p = 0.13), and when stratified by primary site and grade (p = 0.18). Multiple linear regression confirmed no association between visfatin and the study variables (R-squared = 0.036, all p > 0.2). Conclusions: This is the first study examining serum visfatin as a diagnostic biomarker in NETs. Visfatin concentrations show moderate discriminatory ability between NETs and controls, independent of tumor and clinical characteristics. Further research should involve larger cohorts and comparisons to established biomarkers.